A study to investigate changes in symptoms in adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with Tezepelumab

Trial Identifier: D5242C00002
Sponsor: AstraZeneca
Collaborator:
Fortrea
Start Date: December 2024
Primary Completion Date: January 2027
Study Completion Date: January 2027
Condition: Nose and Sinus Disorder

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BG Plovdiv, BG, 4003
BG Sofia, BG, 1431
BG Sofia, BG, 1606
CA, Ontario Hamilton, Ontario, CA, L8S 1G5
CA, QC Quebec, QC, CA, G1L 3L5
CA, QC Quebec, QC, CA, G1V 4W2
DE Düsseldorf, DE, 40225
DE Marburg, DE, 35043
DE Tubingen, DE, 72076
DE Villingen-Schwenningen, DE, 78052
DE Wiesbaden, DE, 65183
ES Barcelona, ES, 08003
ES Barcelona, ES, 08035
ES Cadiz, ES, 11011
ES Madrid, ES, 28041
ES Salamanca, ES, 37007
ES Santiago de Compostela, ES, 15706
FR Le Kremlin-Bicêtre, FR, 94270
FR Lille, FR, 59000
FR Marseille, FR, 13005
FR Nantes Cedex 1, FR, 44093
FR Pierre Benite, FR, 69495
FR Poitiers, FR, 86000
FR Toulouse Cedex 9, FR, 31400
HU Budapest, HU, 1134
HU Budapest, HU, 1085
HU Nyiregyhaza, HU, 4400
HU Pécs, HU, 7621
IT Bologna, IT, 40139
IT Catania, IT, 95123
IT Firenze, IT, 50139
IT Napoli, IT, 80131
IT Padua, IT, 35128
IT PISA, IT, 56126
IT Roma, IT, 00168
IT Rozzano, IT, 20089
PL Bialystok, PL, 15-879
PL Bydgoszcz, PL, 85-231
PL Łódź, PL, 90-302
PL Zawadzkie, PL, 47-120
US, CA Newport Beach, CA, US, 92663
US, IL Chicago, IL, US, 60611
US, MA Chestnut Hill, MA, US, 02467
US, MO Columbia, MO, US, 65201